TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30890120

Group type: EXPERIMENTAL
Intervention: As planned (n=98)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Laggers (n=15)
Number of subjects: 113
Study: 29095990

Group type: EXPERIMENTAL
Intervention: Low-cholesterol, low-fat (LChF) diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-cholesterol, high-fat (HChF) diet
Number of subjects: 30
Study: 26775262

Group type: EXPERIMENTAL
Intervention: Enhanced goal setting linked to a structured incentive scheme (text messages and rewards for achieving goals)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Standard/existing program (no structured incentive program)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Enhanced goal setting linked to a structured incentive scheme
Number of subjects: 570

Group type: COMPARATOR
Intervention: Standard/existing program
Number of subjects: 570
Study: 25188543

Group type: EXPERIMENTAL
Intervention: 3 sessions of an exposure intervention, beginning in the emergency department shortly after trauma exposure
Number of subjects: 65

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 3 sessions of an exposure intervention
Number of subjects: 65
Study: 22270204

Group type: EXPERIMENTAL
Intervention: Dynamiclear formulation (copper sulfate pentahydrate and Hypericum perforatum)
Number of subjects: 149

Group type: COMPARATOR
Intervention: 5% Acyclovir cream
Number of subjects: 149
Study: 20969660

Group type: EXPERIMENTAL
Intervention: DGE (dermal gel extra)
Number of subjects: 140

Group type: COMPARATOR
Intervention: NASHA (nonanimal stabilized HA)
Number of subjects: 140
Study: 17950167

Group type: EXPERIMENTAL
Intervention: Health behavior intervention
Number of subjects: 878

Group type: COMPARATOR
Intervention: SUN protection behaviors (comparison condition)
Number of subjects: 878
Study: 16302455

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine and thymol varnish
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo varnish containing only thymol
Number of subjects: 38
Study: 12475848

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 15
Study: 9665673

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 2 IU/m2 for 12 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 27
Study: 7712610

Group type: EXPERIMENTAL
Intervention: Voltaren drops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Voltaren vehicle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cellufresh (non‐preserved lubricant)
Number of subjects: 30
Study: 2654285

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 14
Study: 31333215

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 294

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 294
Study: 27048345

Group type: EXPERIMENTAL
Intervention: Active IFC
Number of subjects: 75

Group type: COMPARATOR
Intervention: New placebo
Number of subjects: 75

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 75
Study: 26434929

Group type: EXPERIMENTAL
Intervention: Tulip abutment (TA) design
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard platform abutment (SA)
Number of subjects: 27
Study: 23235200

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 21784603

Group type: EXPERIMENTAL
Intervention: Supervised treadmill walking (Exercise)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conservative medical treatment (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (PAD patients and healthy adults)
Number of subjects: 25
Study: 19345452

Group type: EXPERIMENTAL
Intervention: CH‐19 sweet pepper
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin and green tea
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin + green tea
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16696864

Group type: COMPARATOR
Intervention: Fluids alone (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluids and dobutamine (n = 25)
Number of subjects: 50
Study: 15278085

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine (4 mL 10%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (nebulized normal saline solution)
Number of subjects: 50
Study: 11376302

Group type: EXPERIMENTAL
Intervention: Carvedilol (mean daily dose: 58 ± 1 mg)
Number of subjects: 2184

Group type: EXPERIMENTAL
Intervention: Metoprolol (mean daily dose: 162 ± 1 mg)
Number of subjects: 2184

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 2184

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 2184
Study: 9292587

Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg every 4 hours (regimen A)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Zidovudine 300 mg every 12 hours (regimen B)
Number of subjects: 320
Study: 8501929

Group type: EXPERIMENTAL
Intervention: Platelet rich plasma infusion after heparin reversal
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no platelet rich plasma infusion)
Number of subjects: 51
Study: 3682857

Group type: EXPERIMENTAL
Intervention: Right atrial injection of protamine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Left atrial injection of protamine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aortic injection of protamine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 29972818

Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) continuous veno-venous hemodialysis (CVVHD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-flux membrane (HFM) continuous veno-venous hemodiafiltration (CVVHDF)
Number of subjects: 10
Study: 29515279

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg b.i.d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg b.i.d
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg t.i.d
Number of subjects: 90
Study: 26162995

Group type: EXPERIMENTAL
Intervention: Body-contouring procedures (BC) including abdominoplasty (n=20), rectus plication (n=7), liposuction (n=6)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bariatric surgery (BS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Obese group (no surgery)
Number of subjects: 66
Study: 23966023

Group type: EXPERIMENTAL
Intervention: Oral risperidone (open label) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 24
Study: 21961949

Group type: EXPERIMENTAL
Intervention: DiAlert lifestyle education programme
Number of subjects: 268

Group type: COMPARATOR
Intervention: Leaflet (control group)
Number of subjects: 268
Study: 21644418

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol suspension
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vaginally administered misoprostol
Number of subjects: 134
Study: 16646026

Group type: EXPERIMENTAL
Intervention: Alefacept (15 mg) plus methotrexate (MTX) administered intramuscularly once weekly for 12 weeks
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Alefacept (15 mg) plus methotrexate (MTX) in patients with psoriasis involving >= 3% BSA
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX) in patients with psoriasis involving >= 3% BSA
Number of subjects: 185
Study: 12825917

Group type: EXPERIMENTAL
Intervention: Hypnosis-based intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 44
Study: 10773503

Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8665115

Group type: EXPERIMENTAL
Intervention: 15 min at 62.5 W (mean maternal heart rate 138 beats.min‐1) (test A)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15 min at 87.5 W (mean maternal heart rate 156 beats.min‐1) (test B)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 min at 62.5 W (mean maternal heart rate 142 beats.min‐1) (test C)
Number of subjects: 11
Study: 2003533

Group type: EXPERIMENTAL
Intervention: Erythromycin 333 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6360586

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation within the first 12 hours of birth
Number of subjects: 191

Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 191
Study: 30517329

Group type: COMPARATOR
Intervention: Nylon 4.0
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25, 4.0
Number of subjects: 60
Study: 27653448

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection 500 U
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 25162604

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (initiated at 100 µg, titrated to effective dose)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (titration phase)
Number of subjects: 130
Study: 23742699

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7%) inhaled twice daily for 48 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) inhaled twice daily for 48 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Comparison of treatment effects
Number of subjects: 25
Study: 20509919

Group type: EXPERIMENTAL
Intervention: Lung Sealant System (Pleuraseal) applied over air leak areas
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no additional interventions)
Number of subjects: 46
Study: 17717058

Group type: EXPERIMENTAL
Intervention: bladed cleats
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: elliptical firm ground cleats
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: hard ground cleats
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: turf cleats
Number of subjects: 36

Group type: COMPARATOR
Intervention: all cleat types
Number of subjects: 36
Study: 16368836

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study: 12851021

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10728961

Group type: EXPERIMENTAL
Intervention: Intravenous ibutilide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct-current cardioversion
Number of subjects: 0
Study: 8875098

Group type: EXPERIMENTAL
Intervention: Sucralose (1,000 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 26
Study: 1305392

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3927210

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 208
Study: 31311577

Group type: EXPERIMENTAL
Intervention: I-BiT treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 120
Study: 29768152

Group type: EXPERIMENTAL
Intervention: 20 mg cannabidiol group
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 10 mg cannabidiol group
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 225
Study: 27142292

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 60
Study: 24499249

Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 495

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 495
Study: 22773262

Group type: EXPERIMENTAL
Intervention: Training with existing prosthesis and fitting with SACH, SAFE, Talux, and Proprio feet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Existing prosthesis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Proprio foot
Number of subjects: 10
Study: 20207340

Group type: EXPERIMENTAL
Intervention: Senna (8.6 mg) with docusate (50 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 17439572

Group type: EXPERIMENTAL
Intervention: Double cerclage
Number of subjects: 242

Group type: COMPARATOR
Intervention: Single cerclage
Number of subjects: 242
Study: 15632489

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n = 21)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise (n = 21)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 62
Study: 11050694

Group type: EXPERIMENTAL
Intervention: EPI-5 transdermal patch (5 mg GTN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EPI-10 transdermal patch (10 mg GTN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EPI-15 transdermal patch (15 mg GTN)
Number of subjects: 18
Study: 9066350

Group type: EXPERIMENTAL
Intervention: 2 Plasma Exchanges (PEs)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: 4 Plasma Exchanges (PEs)
Number of subjects: 556

Group type: COMPARATOR
Intervention: 6 Plasma Exchanges (PEs)
Number of subjects: 556
Study: 8373607

Group type: EXPERIMENTAL
Intervention: Laryngeal lift maneuver
Number of subjects: 102
Study: 2941572

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg BID
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg BID
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etodolac 600 mg BID
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspirin 975 mg QID
Number of subjects: 48
Study: 31300705

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) formula
Number of subjects: 276

Group type: COMPARATOR
Intervention: Lower protein (LP) formula
Number of subjects: 276
Study: 30267226

Group type: EXPERIMENTAL
Intervention: Barefoot intervention group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Shod intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: COMPARATOR
Intervention: BESS test
Number of subjects: 60
Study: 27625185

Group type: EXPERIMENTAL
Intervention: One-sample instrumental variable estimate with 10% relative bias (F parameter of 10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-sample setting with risk factor measurements only for control participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-sample setting with risk factor data on both control and case participants
Number of subjects: 0
Study: 23737941

Group type: EXPERIMENTAL
Intervention: Water depth of 0.45 m and water speed of 0.4 m/s
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Water depth of 0.90 m and water speed of 0.8 m/s
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Water depth of 0.90 m and water speed of 1.2 m/s
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Prior experience with rip currents and tropical cyclones
Number of subjects: 76
Study: 21999871

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 to 30 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Glimepiride (0.5 to 4.0 mg)
Number of subjects: 56
Study: 18471513

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg intravenously every 6 hours, doubled on day 4 if SCr did not decrease by 30%)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 16199147

Group type: EXPERIMENTAL
Intervention: Men with COPD, BMI 30 kg/m²
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Women with COPD, FEV(1)%FVC<median
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Men with COPD, increasing daily number of cigarettes by 10
Number of subjects: 642

Group type: COMPARATOR
Intervention: Men with COPD
Number of subjects: 642

Group type: COMPARATOR
Intervention: Women with COPD
Number of subjects: 642
Study: 14756934

Group type: EXPERIMENTAL
Intervention: Flow experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition of favorite activities
Number of subjects: 0
Study: 10709160

Group type: EXPERIMENTAL
Intervention: 60 mg oral lansoprazole for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Safety evaluations including adverse events, vital signs, clinical laboratory determinations, ECG, and physical examinations
Number of subjects: 18
Study: 9329355

Group type: EXPERIMENTAL
Intervention: Human recombinant GH replacement therapy for 6 months (period 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH replacement for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 8479462

Group type: EXPERIMENTAL
Intervention: Topical tretinoin (0.1 percent retinoic acid cream)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 54
Study: 3079487

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (including diethylstilbestrol, estramustine phosphate, aminoglutethimide, progestational agents, antiandrogens, orchiectomy, LHRH analogues like leuprolide, and combination hormonal therapies)
Number of subjects: 0
Study: 30326808

Group type: EXPERIMENTAL
Intervention: Anterior thrust spine mobilisations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Posterior thrust spine mobilisations
Number of subjects: 6
Study: 27740724

Group type: EXPERIMENTAL
Intervention: Dornase treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: No dornase treatment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall treatment costs
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Inpatient stays
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Age and clinical risk factors
Number of subjects: 73
Study: 24037670

Group type: EXPERIMENTAL
Intervention: Peetrons grading and specific prognostic MRI parameters
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prognostic MRI parameters
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Specific MRI parameters (distance from ischial tuberosity, extent, maximum cross-sectional area, volume of oedema)
Number of subjects: 25
Study: 23385036

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20797750

Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (DP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cardiac pacemakers
Number of subjects: 20
Study: 18245069

Group type: EXPERIMENTAL
Intervention: Low fidelity model training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High fidelity model training
Number of subjects: 30
Study: 20673545

Group type: EXPERIMENTAL
Intervention: Algorithm-guided treatment
Number of subjects: 429

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Two different treatment algorithms
Number of subjects: 429
Study: 15607689

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saccharin (control)
Number of subjects: 7
Study: 11785838

Group type: EXPERIMENTAL
Intervention: Low-dose chemotherapy with m-BACOD (methotrexate, bleomycin, doxorubicin, vincristine, and dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard-dose m-BACOD with sargramostim (GM-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with 0 or 1 adverse prognostic factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with 3 or 4 adverse prognostic factors
Number of subjects: 0
Study: 9611052

Group type: EXPERIMENTAL
Intervention: Immunologic assay for Chlamydia
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Immunologic assay for HSV 2 IgM
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Immunologic assays for sexually transmitted diseases
Number of subjects: 118

Group type: COMPARATOR
Intervention: Matched control group with normal cervical cytology
Number of subjects: 118
Study: 8156313

Group type: EXPERIMENTAL
Intervention: Day patient care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 20
Study: 3074595

Group type: EXPERIMENTAL
Intervention: diatrizoate 76%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: iopromide 370
Number of subjects: 48
Study: 30088567

Group type: EXPERIMENTAL
Intervention: Mandibular Protraction Appliance (MPA)
Number of subjects: 39
Study: 27163222

Group type: EXPERIMENTAL
Intervention: FFC-AC (Function-Focused Care for Acute Care)
Number of subjects: 89

Group type: COMPARATOR
Intervention: FFC-EO (Function-Focused Care Education Only)
Number of subjects: 89
Study: 25241181

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (formula)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 22033341

Group type: EXPERIMENTAL
Intervention: Pedicle flap design
Number of subjects: 52

Group type: COMPARATOR
Intervention: Buccal envelope flap
Number of subjects: 52
Study: 20728707

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 75 mg indomethacin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 18383146

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16039733

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg orally twice daily for 4 doses
Number of subjects: 95

Group type: COMPARATOR
Intervention: Fenoldopam 0.1 mcg/kg/min intravenously for a minimum of 8 h
Number of subjects: 95